Log in with your email address username.


[Comment] CD8 T cells and mTOR: new concepts and targets for systemic lupus erythematosus

Management of systemic lupus erythematosus and its variable clinical manifestations remain considerable challenges for clinicians and patients. Advances in characterising mechanisms of immune system regulation have been applied to studies of systemic lupus erythematosus, implicating type I interferon and highlighting the contributions of T and B lymphocytes to autoantibody production and tissue damage.1 Despite such progress, the pace of development of more effective therapies for patients has been slow.